Wikström S, Tapper J
Children's Hospital, University of Helsinki, Finland.
Scand J Urol Nephrol Suppl. 1997;183:33-4; discussion 34-5.
The efficacy of repeated treatment attempts using desmopressin (Minirin, DDAVP), either alone, alternately or in combination with an alarm device, were evaluated in 96 patients with primary nocturnal enuresis who were slow, delayed or non-responders to therapy. At follow-up, 52% of the patients were cured and off therapy, an additional 26% had achieved dryness when using desmopressin regularly or on special occasions, and 22% were still wetting. It can be concluded that desmopressin therapy can be successfully commenced at the age of 5 years. Repeated treatment attempts can lead to achievement of dryness at an earlier stage. However, they probably do not influence the final outcome.
对96例原发性夜间遗尿症患者进行了评估,这些患者对治疗反应缓慢、延迟或无反应,采用去氨加压素(弥凝,DDAVP)单独、交替或与警报装置联合进行重复治疗尝试。随访时,52%的患者治愈且停止治疗,另外26%的患者在定期或特殊情况下使用去氨加压素时已实现干爽,22%的患者仍有尿床现象。可以得出结论,去氨加压素治疗可在5岁时成功开始。重复治疗尝试可使患者在更早阶段实现干爽。然而,它们可能不会影响最终结果。